Positive Interaction of Thyme (Red) Essential Oil with Human Polymorphonuclear Granulocytes in Eradicating Intracellular *Candida albicans*

Vivian Tullio[1], Narcisa Mandras[1], Valeria Allizond[1], Antonia Nostro[2], Janira Roana[1], Chiara Merlino[1], Giuliana Banche[1], Daniela Scalas[1], Anna Maria Cuffini[1]

[1] Department of Public Health and Microbiology, University of Turin, Turin, Italy

[2] Pharmaco-Biological Department, University of Messina, Messina, Italy

Abstract

The essential oils have started to be recognized for their potential antimicrobial role only in recent years. Clinical experience showed that the efficacy of antimicrobial agents depends not only on their direct effect on a given microorganism but also on the functional activity of the host immune system. Since data on the effects of essential oils on the innate immune system are scanty and fragmentary, the aim of this study was to evaluate the influence of thyme (red) essential oil (EO), at subinhibitory/inhibitory concentrations, on intracellular killing activity by human polymorphonuclear granulocytes (PMNs) against *Candida albicans*. In order to provide a frame of reference for the activity of this EO, its *in vitro* killing activity in the absence of PMNs was also evaluated.

Results showed that EO at subminimal inhibitory (subMIC)/minimal inhibitory (MIC) concentrations significantly enhanced intracellular killing of *C. albicans* in comparison with EO-free controls and was comparable to the positive control (fluconazole). In *in vitro* killing assays without PMNs, we observed progressive growth of the yeast cells in the presence of EO subMIC/MIC concentrations. A positive antifungal interaction with phagocytes could explain why this EO, which appeared to be only fungistatic in time-kill assays, had efficacy in killing yeast cells once incubated with PMNs.

Key words

thyme (red) essential oil · *Candida albicans* · PMNs · intracellular killing · *in vitro* killing

The increasing recognition and importance of fungal infections, the difficulties encountered in their treatment, and the increase in resistance to antifungal agents have stimulated the search for new therapeutic alternatives [1]. The essential oils and products of plant secondary metabolism had a wide application in folk medicine, fragrance industries, as well as food flavoring and preservation, but only in recent years they have started to be recognized for their potential antimicrobial role [2–4]. The literature reports evidence suggesting that a larger number of plants and their constituents could show beneficial therapeutic effects, including antioxidant, anti-inflammatory, and immunomodulatory activity, which still need to be further investigated [5–9]. In particular, data on the effects of essential oils on the innate immune system are scanty and fragmentary. As PMNs play a pivotal role against invading microbial pathogens, enhanced PMN activity under the essential oils influence may contribute to their anti-infective properties [10,11].

The essential oil from *Thymus vulgaris* L. is widely used in folk medicine for the treatment of a variety of diseases since it possesses numerous biological properties including antibacterial, antifungal, and antioxidant activity [1,3,12–17].

In this paper, we report the interaction of thyme (red) EO with human PMNs, focusing on intracellular killing of *Candida albicans*. As a positive control, we used fluconazole, one of the most common antifungal drugs in candidiasis management, known to enhance the fungicidal activity of PMNs [10]. Moreover, in order to provide a frame of reference for the activity of this EO, its *in vitro* killing in the absence of PMNs was also evaluated.

EO MICs for *C. albicans* were 0.03 and 0.5% v/v, while fluconazole MICs were 0.5 and 8 µg/mL with inocula of 10^3 and 10^6 ufc/mL, respectively. In the absence of PMNs, the EO activity was only fungistatic at all concentrations tested, causing slight reductions (i.e., $\leq 3 \log_{10}$) in the starting inoculum, as shown in **Fig. 1**. At subMIC/MIC concentrations, killing activity was not sustained over time because yeast cell growth was seen at 24 h.

Clinical experience showed that the efficacy of antimicrobial agents depends not only on their direct effect on a given microorganism but also on the functional activity of the immune system [10,11,18]. Results on effects upon the PMNs intracellular killing showed that EO and fluconazole had similar candidacidal activity (**Table 1**). EO at 1 × MIC significantly increased the intracellular killing by phagocytes, with percentages that ranged from 50 to 73%, in comparison with controls (EO-free), ranging from 33 to 50% (**Table 1**; $p < 0.01$). In the presence of 1 × MIC fluconazole, intracellular yeasts were killed at 51–69–75% ($p < 0.01$).

A similar picture was detected even at lower levels of EO (1/2 × MIC), where killing values (44–57–69%) were significantly higher than those of control systems (33–47–50%; $p < 0.05$) and overlapped with those observed in presence of 1/2 × MIC fluconazole (42–58–63%).

The mechanism of such enhancement is still unknown; despite the fact that this EO displayed only a fungistatic action in the absence of PMNs, it showed efficacy in killing yeasts once simultaneously incubated with PMNs, suggesting a positive antifungal interaction with phagocytes, as previously observed with other antifungal agents [10,19].

EO direct damage to the yeast cell may be, at least in part, responsible for changes that make the yeasts more susceptible to PMN lytic mechanisms. The EO used in this study is mainly composed of thymol, *ρ*-cymene, limonene, *α*-pinene, carvacrol, and *γ*-terpinene, at different percentages [3], but it is not clear which of the active ingredients accounted for the observed effect on yeast killing.

Recent literature data reported that thymol and carvacrol exhibit fungicidal activity in a dose-dependent fashion against yeasts, resulting from direct damage to cell membranes [20]. Since essential oils are phytocomplexes containing numerous molecules, their bioactivity could be the result of a synergism of all major and minor components [21,22]. In fact, antifungal susceptibility testing on thymol and carvacrol showed that these components exhibited MIC values higher (0.06% v/v) than those obtained with whole EO (0.03% v/v) against *C. albicans* (data not shown). Further investigations are needed to confirm these findings.



Fig. 1 Effect of thyme (red) essential oil on the *in vitro* killing of *Candida albicans*. *C. albicans* (10^6 cfu/mL) was incubated with the EO at 4% v/v (8 × MIC), 2% v/v (4 × MIC), 1% v/v (2 × MIC), 0.5% v/v (1 × MIC), 0.25% v/v (1/2 × MIC), 0.125% v/v (1/4 × MIC), and 0.06% v/v (1/8 × MIC).

Table 1 Effect of thyme (red) essential oil and fluconazole at 1/2 × MIC/1 × MIC on intracellular killing of *C. albicans* by human PMNs.

	Mean SI ± SEM (% of initial fungal population killed by PMNs in absence or presence of fluconazole or EO)				
Time (min)	Controls	1/2 × MIC fluconazole (4 µg/mL)	1 × MIC fluconazole (8 µg/mL)	1/2 × MIC thyme (red) EO (0.25% v/v)	1 × MIC thyme (red) EO (0.5% v/v)
30	1.67 ± 0.03 (33%)	1.58[b] ± 0.08 (42%)	1.49[a] ± 0.07 (51%)	1.56[b] ± 0.07 (44%)	1.50[a] ± 0.01 (50%)
60	1.53 ± 0.02 (47%)	1.42[b] ± 0.08 (58%)	1.31[a] ± 0.06 (69%)	1.43[b] ± 0.11 (57%)	1.36[a] ± 0.04 (64%)
90	1.50 ± 0.03 (50%)	1.37[b] ± 0.17 (63%)	1.25[a] ± 0.06 (75%)	1.31[b] ± 0.07 (69%)	1.27[a] ± 0.02 (73%)

[a] Significantly different from the controls ($p < 0.01$); [b] significantly different from the controls ($p < 0.05$)

Materials and Methods

A clinical *C. albicans* strain was isolated from blood, identified by conventional methods and subcultured on Sabouraud dextrose agar (SAB). Yeasts cultures consisted entirely of blastoconidia and had a slight tendency to differentiate into pseudohyphae during the course of the experiments [10].

The thyme (red) EO commercially obtained from Azienda Agricola Aboca was the same batch used and characterized by GC-FID analyses in a previous study [3]. Its major constituents were thymol (26.5%), *ρ*-cymene (16.2%), limonene (13.2%), α-pinene (13.2%), carvacrol (7.8%), and γ-terpinene (4%).

Antifungal susceptibility testing was based on the CLSI M27-A3 [23] method, with some modifications; the final EO concentrations ranging from 1 to 0.0019% (v/v). EO and fluconazole (Sigma-Aldrich; purity ≥ 98% by HPLC) MIC values for *C. albicans* were determined with an inoculum of 10^3 cfu/mL and an inoculum of 10^6 cfu/mL to perform tests with and without phagocytes. *In vitro* killing was performed by using a 10^6 cfu/mL starting yeast inoculum and EO at 4% v/v (8 × MIC), 2% v/v (4 × MIC), 1% v/v (2 × MIC), 0.5% v/v (1 × MIC), 0.25% v/v (1/2 × MIC), 0.125% v/v (1/4 × MIC), and 0.06% v/v (1/8 × MIC). EO-free controls were included. 500 µL aliquots were removed at 0, 30, 60, 90, 120, 180 min, and 24 h, serially tenfold diluted and plated onto SAB agar. After 24–48 h at 37 °C, results were reported as log cfu/mL. Fungicidal activity was defined as a 99.9% (≥ 3 $\log_{10}$) reduction in viable cell counts as compared with the starting inoculum [11].

Human PMNs were separated from lithium heparinized venous blood using Ficoll–Paque (Pharmacia S. p. A.) and adjusted to 10^6 cells/mL in RPMI1640 [11]. Viability, determined by trypan blue exclusion, was greater than 95%.

The EO effect on the intracellular killing of *C. albicans* by PMNs was investigated by incubating blastoconidia (10^6 cfu/mL) and PMNs (10^6 cells/mL) for 30 min to allow phagocytosis to proceed. The PMN-yeast cell mixtures were centrifuged at 200 *g* for 5 min to remove extracellular blastoconidia. An aliquot of PMNs was lysed by adding sterile water, and intracellular viable yeast counting was performed (time zero). PMNs were incubated further with 0.25% v/v and/or 0.5% v/v (1/2 MIC and 1 × MIC, respectively) of EO and at time *X* (30, 60, 90 min), the viable counts were measured in the same way. EO-free controls were included. As positive controls, 1/2 × MIC (4 µg/mL) and 1 × MIC (8 µg/mL) fluconazole were included. Killing values were expressed as a survival index (SI), which was calculated by adding the number of surviving blastoconidia at time zero to the number of survivors at time *X* and dividing by the number of survivors at time zero. According to this formula, if fungal killing was 100% effective, the SI would be 1 [10, 11].

Results are expressed as the mean ± standard error of the mean (SEM) of 10 separate experiments, each performed in quadruplicate. Statistical evaluation of the differences between test and control results was performed by Tukey's test. *In vitro* killing was compared using Student's unpaired t-test.

Conflict of Interest

The authors report no conflicts of interest.

Acknowledgements

The authors are grateful to Dr. R. Serra (ASL San Giovanni Battista-Molinette, Turin) for providing the *Candida albicans* strain and to Dr. Gabriella Vecchi for the helpful English revision of the manuscript.

References

1 *Pina-Vaz C, Gonçalves Rodrigues A, Pinto E, Costa-de-Oliveira S, Tavares C, Salgueiro L, Cavaleiro C, Gonçalves MJ, Martinez-de-Oliveira J.* Antifungal activity of *Thymus* oils and their major compounds. J Eur Acad Dermatol Venereol 2004; 18: 73–78
2 *Kalemba D, Kunicka A.* Antibacterial and antifungal properties of essential oils. Curr Med Chem 2003; 10: 813–829
3 *Tullio V, Nostro A, Mandras N, Dugo P, Banche G, Cannatelli MA, Cuffini AM, Alonzo V, Carlone NA.* Antifungal activity of essential oils against filamentous fungi determined by broth microdilution and vapour contact methods. J Appl Microbiol 2007; 102: 1544–1550
4 *Vale-Silva LA, Gonçalves MJ, Cavaleiro C, Salgueiro L, Pinto E.* Antifungal activity of the essential oil of *Thymus x viciosoi* against *Candida, Cryptococcus, Aspergillus* and dermatophyte species. Planta Med 2010; 76: 882–888
5 *Abe S, Maruyama N, Hayama K, Ishibashi H, Inoue S, Oshima H, Yamaguchi H.* Suppression of tumour necrosis factor-alpha-induced neutrophil adherence responses by essential oils. Mediators Inflamm 2003; 12: 323–328
6 *Chao LK, Hua KF, Hsu HY, Cheng SS, Lin IF, Chen CJ, Chen ST, Chang ST.* Cinnamaldehyde inhibits pro-inflammatory cytokines secretion from monocytes/macrophages through suppression of intracellular killing. Food Chem Toxicology 2008; 46: 220–231
7 *Conrad A, Hansmann C, Engels I, Daschner FD, Frank U.* Extract of *Pelargonium sidoides* (EPs®7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes *in vitro*. Phytomedicine 2007; 14: 46–51
8 *Salem ML.* Immunomodulatory and therapeutic properties of the *Nigella sativa* L. seed. Int Immunopharmacol 2005; 5: 1749–1770
9 *Amirghofran Z, Hashemzadeh R, Javidnia K, Golmoghaddam H, Esmaeilbeig AJ. In vitro* immunomodulatory effects of extracts from three plants of the Labiatae family and isolation of the active compound(s). J Immunotoxicol 2011; 8: 265–273
10 *Tullio V, Cuffini AM, Giacchino F, Mandras N, Roana J, Comune L, Merlino C, Carlone NA.* Combined action of fluconazole and PMNs from uremic patients in clearing intracellular *Candida albicans*. J Chemother 2003; 15: 301–303
11 *Tullio V, Cuffini AM, Banche G, Mandras N, Allizond V, Roana J, Giacchino F, Bonello F, Ungheri D, Carlone NA.* Role of fosfomycin tromethamine in modulating non-specific defence mechanisms in chronic uremic patients towards ESBL-producing *Escherichia coli.* Int J Immunopathol Pharmacol 2008; 21: 153–160
12 *Rustaiyan A, Masoudi S, Monfared A, Kamalinejad M, Lajevardi T, Sedaghat S, Yari M.* Volatile constituents of three *Thymus* species grown wild in Iran. Planta Med 2000; 66: 197–198
13 *Marino M, Bersani C, Comi G.* Antimicrobial activity of the essential oils of *Thymus vulgaris* L. measured using a bioimpedometric method. J Food Prot 1999; 62: 1017–1023
14 *Palmeira-de-Oliveira A, Salgueiro L, Palmeira-de-Oliveira R, Martinez-de-Oliveira J, Pina-Vaz C, Queiroz JA, Rodrigues AG.* Anti-Candida activity of essential oils. Mini Rev Med Chem 2009; 9: 1292–1305
15 *Soković MD, Vukojević J, Marin PD, Brkić DD, Vajs V, van Griensven LJ.* Chemical composition of essential oils of *Thymus* and *Mentha* species and their antifungal activities. Molecules 2009; 14: 238–249
16 *Grosso C, Figueiredo AC, Burillo J, Mainar AM, Urieta JS, Barroso JG, Coelho JA, Palavra AM.* Composition and antioxidant activity of *Thymus vulgaris* volatiles: comparison between supercritical fluid extraction and hydrodistillation. J Sep Sci 2010; 33: 2211–2218
17 *El-Nekeety AA, Mohamed SR, Hathout AS, Hassan NS, Aly SE, Abdel-Wahhab MA.* Antioxidant properties of *Thymus vulgaris* oil against aflatoxin-induce oxidative stress in male rats. Toxicon 2011; 57: 984–991
18 *Cuffini AM, Tullio V, Mandras N, Roana J, Banche G, Carlone NA.* The leading role of antimicrobial agents in modulating the binomial host-microorganism. Curr Med Chem Anti Infect Agents 2004; 3: 1–13
19 *Tullio V, Mandras N, Scalas D, Allizond V, Banche G, Roana J, Greco D, Castagno F, Cuffini AM, Carlone NA.* Synergy of caspofungin with human polymorphonuclear granulocytes for killing *Candida albicans*. Antimicrob Agents Chemother 2010; 54: 3964–3966
20 *Ahmad A, Khan A, Akhtar F, Yousuf S, Xess I, Khan LA, Manzoor N.* Fungicidal activity of thymol and carvacrol by disrupting ergosterol biosynthesis and membrane integrity against Candida. Eur J Clin Microbiol Infect Dis 2011; 30: 41–50
21 *Bakkali F, Averbeck S, Averbeck D, Idaomar M.* Biological effects of essential oils – a review. Food Chem Toxicol 2008; 46: 446–475
22 *Mickienė R, Bakutis B, Baliukoniene V.* Antimicrobial activity of two essential oils. Ann Agric Environ Med 2011; 18: 139–144
23 *Clinical and Laboratory Standards Institute.* Reference method for broth dilution antifungal susceptibility testing of yeasts, third edition. Approved standard M27-A3. Wayne: Clinical and Laboratory Standards Institute; 2008

received May 9, 2012
revised July 4, 2012
accepted July 12, 2012

Bibliography
DOI http://dx.doi.org/10.1055/s-0032-1315153
Published online August 7, 2012
Planta Med 2012; 78: 1633–1635

ISSN 0032-0943

Correspondence
Prof. Vivian Tullio
Department of Public Health and Microbiology
Microbiology Section
University of Turin
Via Santena 9
10126 Turin
Italy
Phone: + 39 01 16 70 56 37
Fax: + 39 01 12 36 56 37
vivian.tullio@unito.it